Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MATINAS BIOPHARMA HOLDINGS, INC.

(MTNB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Matinas BioPharma : Piper Sandler Cuts Matinas BioPharma Holdings to Neutral From Overweight, Price Target to $0.90 From $4

05/11/2021 | 11:02am EST


ę MT Newswires 2021
All news about MATINAS BIOPHARMA HOLDINGS, INC.
01/25MATINAS BIOPHARMA : Provides Business Update and 2022 Strategic Outlook - Form 8-K
PU
01/25MATINAS BIOPHARMA HOLDINGS, INC. : Regulation FD Disclosure, Other Events, Financial State..
AQ
01/25Matinas BioPharma Provides Business Update and 2022 Strategic Outlook
GL
01/18Matinas BioPharma to Provide Corporate Update and 2022 Business Outlook on January 25, ..
AQ
2021Matinas BioPharma Says Data Monitoring Panel Backs Continuation of Meningitis Trial to ..
MT
2021MATINAS BIOPHARMA : Announces Unanimous DSMB Approval to Progress into Fourth and Final Co..
PU
2021MATINAS BIOPHARMA HOLDINGS, INC. : Regulation FD Disclosure, Other Events, Financial State..
AQ
2021Matinas BioPharma Announces Unanimous DSMB Approval to Progress into Fourth and Final C..
GL
2021Matinas Biopharma Announces Unanimous Dsmb Approval to Progress into Fourth and Final C..
CI
2021Matinas BioPharma Holdings Names Chief Business Officer
MT
More news
Analyst Recommendations on MATINAS BIOPHARMA HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2021 0,36 M - -
Net income 2021 -24,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,88x
Yield 2021 -
Capitalization 152 M 152 M -
Capi. / Sales 2021 421x
Capi. / Sales 2022 55,6x
Nbr of Employees 20
Free-Float 96,0%
Chart MATINAS BIOPHARMA HOLDINGS, INC.
Duration : Period :
Matinas BioPharma Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 0,71 $
Average target price 2,75 $
Spread / Average Target 290%
EPS Revisions
Managers and Directors
Jerome D. Jabbour President, Chief Executive Officer & Director
Keith A. Kucinski Chief Financial Officer
Herbert J. Conrad Chairman
Raphael J. Mannino Chief Scientific Officer & Senior Vice President
James J. Ferguson Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
MATINAS BIOPHARMA HOLDINGS, INC.-33.66%145
MODERNA, INC.-39.94%61 847
LONZA GROUP AG-20.30%49 060
IQVIA HOLDINGS INC.-16.27%45 129
SEAGEN INC.-19.08%22 875
ICON PUBLIC LIMITED COMPANY-19.15%20 381